^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
lenalidomide (STAR-LLD SC)
i
Other names: STAR-LLD SC, CMIO-LLD SC, Star lenalidomide programme
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Starton Therap
Drug class:
TNFα inhibitor, IL-10 stimulant, IL-1β inhibitor, IL-2 stimulant, VEGF inhibitor, FGF inhibitor, IFNγ stimulant, IL-6 stimulant, IL-8 stimulant
Related drugs:
6ms
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) (clinicaltrials.gov)
P1/2, N=24, Recruiting, Starton Therapeutics, Inc | Trial completion date: Sep 2024 --> Mar 2027 | Trial primary completion date: Jul 2024 --> May 2026
Trial completion date • Trial primary completion date
|
bortezomib • lenalidomide (STAR-LLD SC)
Share via
